GlassScriptPhysician profile
Randa M Hamadeh
NPI 1184698151
$947.30
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $189 · 2021: $195.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $220.24 | 2019-2021 | |
| Gilead Sciences, INC. | $142.12 | 2019-2021 | |
| Lilly USA, LLC | $126.88 | 2019-2021 | |
| Amarin Pharma, INC. | $103.66 | 2019-2021 | |
| Glaxosmithkline, LLC. | $93.03 | 2019-2020 | |
| Indivior INC. | $72.19 | 2019-2020 | |
| Amgen INC. | $41.52 | 2019 | |
| Medtronic, INC. | $27.14 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.92 | 2019 | |
| Abbvie INC. | $14.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.98 | 2019 | |
| Pfizer INC. | $13.76 | 2019 | |
| Dynavax Technologies Corporation | $13.41 | 2021 | |
| Becton, Dickinson and Company | $12.67 | 2021 | |
| Scilex Pharmaceuticals INC. | $12.49 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $12.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randa Hamadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.